|Bid||57.09 x 1200|
|Ask||59.64 x 1200|
|Day's Range||56.10 - 57.91|
|52 Week Range||7.05 - 63.40|
|Beta (5Y Monthly)||1.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2023 - Nov 18, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.45|
Subscribe to Yahoo Finance Plus to view Fair Value for MLTX
Nvidia stock has tripled, but it's not No. 1 in 2023. Carvana has surged 996%, leading seven huge winners this year.
ACELYRIN (SLRN) fails to achieve statistically significant primary endpoint result in the hidradenitis suppurativa study of its lead candidate, izokibep. The stock of the company falls 54%.
MoonLake shares rocketed Tuesday after rival Acelyrin reported a failure for its skin disease treatment. MLTX stock neared a record.